ASAdnan Said

Adnan Said

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adnan Said has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Erin Spengler

    Division of Gastroenterology, Department of Medicine University of Texas Health—San Antonio San Antonio Texas USA

    3 shared publications
  • Jennifer C. Lai

    Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California, USA

    3 shared publications
  • Michael R Lucey

    3 shared publications
  • Sonali Paul

    Department of Internal Medicine, Section of Gastroenterology, Hepatology, and Nutrition The University of Chicago Medicine Chicago Illinois USA

    3 shared publications
  • Advancing Liver Therapeutic Approaches (ALTA) Study Group

    2 shared publications
  • Aiman Ghufran

    Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI 53226, United States

    2 shared publications

Latest Publications

  • Open Access

    Inflammatory Hilar Mass and Cavernous Transformation in Disseminated Histoplasmosis: A Rare Cause of Noncirrhotic Portal Hypertension

    by Katharine Tippins, Elizabeth C. Townsend, Franklyn Wallace, Heip Phan, Charles T. Rohrer, Adnan Said

    Disseminated histoplasmosis is a fungal infection usually encountered in immunocompromised hosts. Hepatic involvement is common, but portal hypertension due to extrahepatic lymph node compression has not been described. We present a 68-year-old man without cirrhosis who developed noncirrhotic portal hypertension by reactive, fibrosing porta hepatis lymphadenopathy after disseminated histoplasmosis treatment. Despite prior exposure to immunosuppressive therapy for presumed sarcoidosis, liver biopsy demonstrated preserved hepatic architecture and normal hepatic venous pressure gradient, supporting a presinusoidal, extrahepatic mechanism. This case highlights a novel, compressive cause of noncirrhotic portal hypertension and underscores the importance of recognizing immune reconstitution inflammatory responses in disseminated histoplasmosis.

  • Portal Hypertensive Gastropathy and MELD‐Na Score Predict Recurrent Gastrointestinal Bleeding After TIPSS: An ALTA Group Study

    by Kelly Hu, Mai Sedki, Allison Kwong, Andrew Kesselman, Kanti Pallav Kolli, Giuseppe Morelli, Erin Spengler, Adnan Said, Jennifer Lai, Archita Desai, et al.

    Background: Transjugular intrahepatic portosystemic shunt (TIPSS) is highly effective for treatment of variceal bleeding; however, factors contributing to rebleeding complications remain unclear.Aims: In this study, we aim to determine risk factors for recurrent portal hypertensive gastrointestinal bleeding following TIPSS.Methods: Utilising the Advancing Liver Therapeutic Approaches multicentre database, we retrospectively identified adult patients who underwent TIPSS for secondary prophylaxis of variceal bleeding and had a gastrointestinal rebleeding event within 1 year. We developed multivariable logistic regression models to identify clinical/procedural characteristics associated with rebleeding.Results: We identified 476 patients, predominately middle‐aged (mean age 57), male (62%) and White (65%), with mean MELD‐Na 16. 16% (n = 77) had a rebleeding event; these patients were more likely to be male (p = 0.016), with higher serum creatinine (p = 0.005), MELD‐Na (p = 0.0002), portal hypertensive gastropathy on pre‐TIPSS upper endoscopy (p = 0.000) and with higher incidence of TIPSS revision (p = 0.000). There were no significant differences in type of TIPSS endoprosthesis, concurrent embolotherapy, and post‐TIPSS pressure gradients between those who experienced rebleeding and those who did not. After adjusting for TIPSS revision, multivariable analysis revealed MELD‐Na and presence of portal hypertensive gastropathy on pre‐TIPSS endoscopy were independently associated with rebleeding.Conclusions: In this retrospective analysis of a multicentre, nationally representative database, we found that apart from TIPSS‐related factors, high MELD‐Na and portal hypertensive gastropathy on pre‐TIPSS endoscopy were independent predictors of rebleeding within 1 year following TIPSS. These variables may be used to identify high‐risk patients who may require additional monitoring following TIPSS.


  • Change in Platelet Count after Transjugular Intrahepatic Portosystemic Shunt Creation: An Advancing Liver Therapeutic Approaches (ALTA) Group Study

    by Randi J. Wong, Jin Ge, Justin Boike, Margarita German, Giuseppe Morelli, Erin Spengler, Adnan Said, Archita Desai, Thomas Couri, Sonali Paul, et al.


  • Microwave Ablation as Bridging to Liver Transplant for Patients with Hepatocellular Carcinoma: A Single-Center Retrospective Analysis

    by Allison B. Couillard, Emily A. Knott, Annie M. Zlevor, Joshua D. Mezrich, Mircea M. Cristescu, Parul Agarwal, Timothy J. Ziemlewicz, Colin Longhurst, Meghan G. Lubner, J. Louis Hinshaw, et al.


  • Open Access

    Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics

    by Imaad Said, Hassan Ahad, Adnan Said

    Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics


  • Sleep disruption in nonalcoholic fatty liver disease: What is the role of lifestyle and diet?

    by Siddique T. Akram, Matthew W. Ewy, Adnan Said

    Background: Patients with nonalcoholic fatty liver disease (NAFLD) have sleep disruption. The aim of this study is to understand how underlying factors such as diet, degree of liver disease and morningness–eveningness tendencies contribute to this sleep disruption. Methods: Patients with NAFLD were recruited from liver clinics at a University and Veterans Affairs practice. Patients with decompensated cirrhosis were excluded. Patients completed self-reported surveys to evaluate sleep disturbance using the Epworth Sleepiness Scale (ESS) and chronotype (circadian preference) using the morningness–eveningness questionnaire (MEQ). Information on occupation, physical activity and dietary intake were collected at clinic intake. Dietary intake was evaluated via food-frequency questionnaire and analyzed as individual categories or grouped on the basis of dietary composition. Results: A 54 patients completed the survey; 37% were female. Median ESS was 8 ± 4.2 and 37% of NAFLD patients were found to have sleep disturbance as defined by ESS >10. Sleep disturbance was common in NAFLD regardless of the liver disease stage. Dietary factors, including higher added sugar (P = 0.01), candy intake (P = 0.01), elevated Ferritin level (P = 0.04) and elevated platelet count (P = 0.05), were significantly associated with sleep disturbance. Chronotype, time to sleep, and duration of sleep were not associated with sleep disruption. Conclusions: Sleep disruption is present in NAFLD regardless of underlying cirrhosis. Interventions aimed at improving dietary and lifestyle practices such as reduced sugar intake may help mitigate the risk for sleep disruption in NAFLD. Further longitudinal studies are needed to further delineate these links.


  • Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post–Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study

    by Jin Ge, Jennifer C. Lai, Justin Richard Boike, Margarita German, Nathaniel Jest, Giuseppe Morelli, Erin Spengler, Adnan Said, Alexander Lee, Alexander Hristov, et al.

    Transjugular intrahepatic portosystemic shunt (TIPS) is an effective intervention for portal hypertensive complications, but its effect on renal function is not well characterized. Here we describe renal function and characteristics associated with renal dysfunction at 30 days post‐TIPS. Adults with cirrhosis who underwent TIPS at 9 hospitals in the United States from 2010 to 2015 were included. We defined “post‐TIPS renal dysfunction” as a change in estimated glomerular filtration rate (ΔeGFR) ≤−15 and eGFR ≤ 60 mL/min/1.73 m2 or new renal replacement therapy (RRT) at day 30. We identified the characteristics associated with post‐TIPS renal dysfunction by logistic regression and evaluated survival using adjusted competing risk regressions. Of the 673 patients, the median age was 57 years, 38% of the patients were female, 26% had diabetes mellitus, and the median MELD‐Na was 17. After 30 days post‐TIPS, 66 (10%) had renal dysfunction, of which 23 (35%) required new RRT. Patients with post‐TIPS renal dysfunction, compared with those with stable renal function, were more likely to have nonalcoholic fatty liver disease (NAFLD; 33% versus 17%; P = 0.01) and comorbid diabetes mellitus (42% versus 24%; P = 0.001). Multivariate logistic regressions showed NAFLD (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.00‐4.17; P = 0.05), serum sodium (Na; OR, 1.06 per mEq/L; 95% CI, 1.01‐1.12; P = 0.03), and diabetes mellitus (OR, 2.04; 95% CI, 1.16‐3.61; P = 0.01) were associated with post‐TIPS renal dysfunction. Competing risk regressions showed that those with post‐TIPS renal dysfunction were at a higher subhazard of death (subhazard ratio, 1.74; 95% CI, 1.18‐2.56; P = 0.01). In this large, multicenter cohort, we found NAFLD, diabetes mellitus, and baseline Na associated with post‐TIPS renal dysfunction. This study suggests that patients with NAFLD and diabetes mellitus undergoing TIPS evaluation may require additional attention to cardiac and renal comorbidities before proceeding with the procedure.


  • Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report

    by Adnan Said, Matthew Weiss, Anna Varhelyi, Rebecca Farago, Cristy Ballweg, John Rice, Parul Agarwal, Luis Fernandez, David Foley

    Background: We report our experience utilizing liver donors with HCV Viremia (RNA+) for HCV‐negative recipients (HCV D+R−) at a Veterans Affairs (VA) transplant center.Methods: In 2018, we introduced an informed consent process for HCV D+R− liver transplants.Results: Eight HCV D+R− liver transplants (LT) were performed. Median time from listing to LT was 189 days (range 41‐511). Median MELD at LT was 23.5 (median MELD at LT of 31 for center). All recipients developed HCV viremia after transplant. Median time to DAA initiation was 10 days after viremia (range 3‐25). After transplant, the DAAs used were Mavyret in five recipients and Epclusa in three, all for 12 weeks. All eight patients completed DAA therapy and achieved negative HCV RNA by end of therapy (ETR) and seven reached sustained virologic response (SVR) by 12 weeks after end of therapy. One patient died from chronic ischemic encephalopathy after ETR, before SVR.Conclusions: HCV D+R− is a practical strategy to expand the pool of donor organs. It shortened waiting time, allowing patients to receive transplants at lower MELD scores. VA liver transplant programs have provided universal and timely access to post‐transplant HCV DAA therapy after donor‐derived infection.


  • Open Access

    In‐Person Outreach and Telemedicine in Liver and Intestinal Transplant: A Survey of National Practices, Impact of Coronavirus Disease 2019, and Areas of Opportunity

    by Courtney B. Sherman, Adnan Said, Michael Kriss, Vishnu S. Potluri, Josh Levitsky, Peter P. Reese, Judy A. Shea, Marina Serper

    Little is known about national practices and use of in‐person outreach clinics and telemedicine in transplantation. We initially aimed to assess contemporary use of in‐person outreach and telemedicine in liver and intestinal transplantation in the U.S. We conducted a national survey of liver and intestinal transplant programs to assess use of outreach and telemedicine from January to March of 2019. Given the coronavirus disease 2019 (COVID‐19) pandemic, we distributed a second survey wave in April 2020 to assess changes in telemedicine use. Of the 143 programs surveyed, the initial response rate was 51% (n=73) representing all 11 Organ Procurement and Transplantation Network (OPTN) regions and 29 states. Pre‐COVID‐19, a total of 42 (59%) surveyed programs had in‐person outreach clinics only while 12 (16%) programs in only 6 states used telemedicine. Centers with higher median MELD at transplant were more likely to utilize telemedicine (p=0.02). During the COVID‐19 pandemic, among 55 of the 73 original responding programs (75%) from all 11 OPTN regions, telemedicine use increased from 16% to 98% and was used throughout all phases of transplant care. Telemedicine utilization was very low prior to COVID‐19 and has increased rapidly across all phases of transplant care presenting an opportunity to advocate for sustained future use.